Drugs Made In America Acquisition II Corp

Research Drugs Made In America Acquisition II Corp (DMII) on Bullrun: market cap USD 646.56M, P/E 49.9. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 646.56M; P/E is 49.9.

Peer valuation comparison

Latest P/E is 49.85x versus a Financial Services sector median of 13.84x (260.3% above).

Latest P/E is 49.85x versus a United States median of 24.87x (100.5% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0USD 4.19M-USD 1.02Mn/an/aUSD 223USD 297.29K-USD 17.77M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 646.56M49.9n/an/a
20252025-12-31USD 630.63M141.4n/an/a

About Drugs Made In America Acquisition II Corp

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.

Related stock research

Other Financial Services stocks

Frequently asked questions

What is Drugs Made In America Acquisition II Corp's market cap?

Drugs Made In America Acquisition II Corp's market capitalization is USD 646.56M.

What is Drugs Made In America Acquisition II Corp's P/E ratio?

Drugs Made In America Acquisition II Corp's price-to-earnings (P/E) ratio is 49.9.

What does Drugs Made In America Acquisition II Corp do?

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.